Follow-up Yttrium-90 Internal Pair Production PET/CT vs Brehmsstrahlung Imaging in Patients With Primary/Metastatic Liver Tumors
| Status: | Completed |
|---|---|
| Conditions: | Liver Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/31/2017 |
| Start Date: | April 2013 |
| End Date: | October 2016 |
Follow-up Yttrium-90 Internal Pair Production PET/CT Imaging in Patients With Primary or Metastatic Liver Tumors as Compared With Brehmsstrahlung Imaging: A Prospective Case Series
This is a prospective non-blinded case series involving the acquisition of a pair production
PET/CT as soon as possible after an already performed Y-90 Sirspheres treatment of hepatic
malignancy. It will be performed in addition to the standard Brehmsstrahlung SPECT scan. The
sequence of the two scans in each case (PET/CT vs SPECT) will be determined by availability
of the scanners at the time. However, it is intended that both be acquired on the day of the
Y-90 treatment.
The length of subject participation will be one year.
The measures used will be mostly qualitative in nature, and will include:
- Correlation with expected vs. achieved tumor coverage by the treatment
- Correlation between treatment distribution depicted by Brehmsstrahlung scans vs. the
Internal Pair Production PET/CT scans, to.
- Detection of non-target embolization, where applicable, and qualitative comparison
between the two modalities as to the conspicuity of the abnormality
Qualitative methods will be used by the analysis of the obtained PET/CT images and comparing
them to the Brehmsstrahlung SPECT images as previously described.
PET/CT as soon as possible after an already performed Y-90 Sirspheres treatment of hepatic
malignancy. It will be performed in addition to the standard Brehmsstrahlung SPECT scan. The
sequence of the two scans in each case (PET/CT vs SPECT) will be determined by availability
of the scanners at the time. However, it is intended that both be acquired on the day of the
Y-90 treatment.
The length of subject participation will be one year.
The measures used will be mostly qualitative in nature, and will include:
- Correlation with expected vs. achieved tumor coverage by the treatment
- Correlation between treatment distribution depicted by Brehmsstrahlung scans vs. the
Internal Pair Production PET/CT scans, to.
- Detection of non-target embolization, where applicable, and qualitative comparison
between the two modalities as to the conspicuity of the abnormality
Qualitative methods will be used by the analysis of the obtained PET/CT images and comparing
them to the Brehmsstrahlung SPECT images as previously described.
Inclusion Criteria:
- Recipient of Selective Internal Radiation Treatment within 5 days.
- Anticipated ability to remain still for up to 40 minutes
Exclusion Criteria:
- Anticipated Inability to lie still for up to 40 minutes
- Severe claustrophobia
- Significant cardiovascular instability, or instability of other medical/surgical
conditions, such that it would be deemed unsafe or technically not feasible to obtain
a PET/CT, as determined by the any member of the investigative team
- Failed deployment of the planned Y-90 treatment for any reason
- Duration of time longer than 5 days since administration of the Y-90 treatment
- Age <18
- Known pregnancy
We found this trial at
1
site
Miami, Florida 33176
Principal Investigator: Jason Salsamendi, MD
Phone: 305-585-8339
Click here to add this to my saved trials
